Company Overview and News

25
Cytori Therapeutics Reminds Investors of Today’s Deadline to be a Shareholder of Record

2018-06-22 globenewswire
- To be a shareholder of record, investors are advised to own Cytori stock by market close on Friday, June 22, 2018 to account for T+2 settlement timing
CYTXW CYTX CTYX

25
Cytori Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering

2018-06-12 globenewswire
SAN DIEGO, June 12, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (Nasdaq:CYTX) ("Cytori"), today provided an informational update to stockholders regarding its proposed rights offering and the expected key dates and terms relative to the offering. Stockholders are advised to ensure they complete their open market purchases of Cytori common stock by Friday, June 22, 2018 to be considered a stockholder of record on Tuesday, June 26, 2018.
CYTXW CYTX CTYX

22
CYTX / Cytori Therapeutics, Inc. / Postfinance Ag - SC 13G/A (Passive Investment)

2018-05-25 sec.gov
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
CYTX

21
CYTX / Cytori Therapeutics, Inc. / Postfinance Ag - SC 13G/A (Passive Investment)

2018-05-25 sec.gov
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
CYTX

27
ECA2018-84 - Reverse Split and CUSIP Number Change for Cytori Therapeutics Inc. (CYTX)

2018-05-23 nasdaqtrader
Cytori Therapeutics Inc. (CYTX) will effect a one-for-ten (1-10) reverse split of its common stock. The reverse stock split will become effective on Thursday, May 24, 2018. In conjunction with the reverse split, the CUSIP number will change to 23283K402.
CYTXW CYTX CTYX

26
Cytori Therapeutics' (CYTX) CEO Marc Hedrick on Q1 2018 Results - Earnings Call Transcript

2018-05-11 seekingalpha
Good afternoon, ladies and gentlemen. Welcome to Cytori Therapeutics First Quarter 2018 Earnings Results Call. At this time, all participants have been placed in a listen-only mode and the floor will be opened for questions following the presentation. [Operator Instructions]
CYTXW CYTX CTYX

25
Cytori Reports Q1 2018 Business and Financial Results

2018-05-10 globenewswire
SAN DIEGO, May 10, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics (NASDAQ:CYTX) (“Cytori” or the “Company”) today announced Q1 2018 financial results and provided updates on corporate development.
CYTXW CYTX CTYX

25
Cytori to Webcast First Quarter Financial Results on May 10

2018-05-07 globenewswire
SAN DIEGO, May 07, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) will provide a live webcast of its first quarter financial results and business update on Thursday, May 10, 2018 at 5:30 PM Eastern Time.
CYTXW CYTX CTYX

24
CYTX / Cytori Therapeutics, Inc. / Postfinance Ag - SC 13G/A (Passive Investment)

2018-04-10 sec.gov
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
CYTX

22
CYTX / Cytori Therapeutics, Inc. / Postfinance Ag - SC 13G/A (Passive Investment)

2018-04-10 sec.gov
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
CYTX

25
Enrollment Completed in ADRESU Clinical Trial of Cytori Cell Therapy™ for Stress Urinary Incontinence

2018-03-28 globenewswire
SAN DIEGO and TOKYO, March 28, 2018 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced today that full enrollment has been reached in the ADRESU investigator-initiated clinical trial of Cytori Cell Therapy™ for men with stress urinary incontinence as a complication of prostate intervention. A total of 45 patients, all treated in Japan, were enrolled in this potential approval trial.
CYTXW CYTX CTYX

25
BRIEF-Cytori Therapeutics - Co Met With U.S. FDA To Discuss Outcome Of Star Clinical Trial

2018-03-16 reuters
* CYTORI THERAPEUTICS - ON MARCH 1, CO MET WITH U.S. FDA TO DISCUSS OUTCOME OF STAR CLINICAL TRIAL AND CO’S PLANS FOR HABEO CELL THERAPY - SEC FILING
CYTXW CYTX

20
CYTX / Cytori Therapeutics, Inc. 8-K (Current Report)

2018-03-16 sec.gov
cytx-8k_20180313.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION
CYTX

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Silicon Investor Message Boards

This table lists all message boards related to CYTX / Cytori Therapeutics, Inc. on message board site Silicon Investor.

Cytori Therapeutics, Inc.
CUSIP: 23283K105